Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Latuda Granted European Regulatory Approval: DSP, Takeda
April 2, 2014
- Abbott Japan Takes Over Marketing Approval for Duphaston from Daiichi Sankyo
April 2, 2014
- Kyowa Kirin Files Nesp in Japan for Anemia in Myelodysplastic Syndrome
April 2, 2014
- Japan Vaccine Files NDA for Pneumococcal Conjugate Vaccine in Japan
April 2, 2014
- US Biotech NPS Takes Aim at Japan Debut around 2017
April 1, 2014
- Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
- Otsuka Acquires Rights for Dacogen from Eisai US Subsidiary
April 1, 2014
- Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
- AnGes MG to Procure 500 Million Yen through Allocation of New Shares to Third Party, to Invest in Orphan Drug Licensing
March 31, 2014
- Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
- Uniform Pricing of Generics into 3 Price Brackets Will Make It More Difficult to Set Invoice Prices: Pres. Yoshiwaka of Daiichi Sankyo Espha
March 28, 2014
- Takeda, Otsuka to Copromote Takeda’s Novel Acid-Related Disease Treatment Vonoprazan
March 28, 2014
- Cetirizine Generics to Carry 3 Prices, Down from 13: Jiho Tally
March 27, 2014
- Qualified Bidders Selected in 1st Qol-Led Open Tender
March 27, 2014
- PII Study of Anti-PCSK9 Antibody in Japanese Patients Meets Primary Endpoint: Amgen Astellas
March 27, 2014
- Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
- DSP’s Antipsychotic Agent Latuda Gets OK in Australia
March 26, 2014
- MHLW Approves Toyama Chemical’s Novel Anti-Influenza Drug Avigan Tablets
March 26, 2014
- Mitsui Becomes Largest Shareholder of Fuji Pharma through Capital, Business Alliance
March 26, 2014
- Otsuka’s Samsca Approved in Japan as World’s 1st ADPKD Treatment
March 26, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…